2014年美国临床肿瘤学会《HER-2阳性晚期乳腺癌脑转移患者的管理建议》被引量：1

导出

摘要美国临床肿瘤学会（ American Society of Clinical Oncology ， ASCO ）于2014年5月5日在《临床肿瘤学杂志》（ JCO ）在线发布了两个关于HER-2阳性晚期乳腺癌治疗的临床指南，分别是《HER-2阳性晚期乳腺癌的系统性全身治疗》［1］和《HER-2阳性晚期乳腺癌脑转移患者的管理建议》［2］，后者是关于HER-2阳性乳腺癌脑转移的首个指南（以下简称指南）。本文详细解读之。

作者王中华胡夕春

机构地区复旦大学附属肿瘤医院肿瘤内科

出处《中华乳腺病杂志（电子版）》 CAS 2014年第4期5-8,共4页 Chinese Journal of Breast Disease(Electronic Edition)

关键词脑转移乳腺肿瘤人表皮生长因子受体2 指南

分类号 R737.9 [医药卫生—肿瘤] R-0 [医药卫生]

引文网络
相关文献

参考文献12

1Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapyfor patients with advanced human epidermal growth factorreceptor 2-positive breast cancer : American Society of ClinicalOncology clinical practice guideline [ J ]. J Clin Oncol,2014,32(19) :2078-2099.
2Ramakrishna N, Temin S, Chandarlapaty S, et al.Recommendations on disease management for patients withadvanced human epidermal growth factor receptor 2-positivebreast cancer and brain metastases : American Society ofClinical Oncology clinical practice guideline [ J ]. J Clin Oncol,2014,32(19) :2100-2108.
3Lin NU, Bellon JR, Winer EP. CNS metastases in breastcancer[J]. J Clin Oncol, 2004, 22(17) : 3608-3617.
4Brufsky AM, Mayer M, Rugo HS, et al. Central nervoussystem metastases in patients with HER2-positive metastaticbreast cancer : Incidence, treatment, and survival in patientsfrom registHER [ J ]. Clin Cancer Res,2011, 17 ( 14 ):48344843.
5Olson EM,Najita JS,Sohl J,et al. Clinical outcomes andtreatment practice patterns of patients with HER2-positivemetastatic breast cancer in the post-trastuzumab era [ J ].Breast, 2013,22(4) :525-531.
6Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapsesin patients with HER2-positive early breast cancer who have andhave not received adjuvant trastuzumab: a retrospectivesubstudy of the HERA trial ( BIG 1-01) [ J]. Lancet Oncol,2013,14(3):244-248.
7Hess KH, Esteva FJ. Effect of HER2 status on distantrecurrence in early stage breast cancer[ J] . Breast Cancer ResTreat, 2013,137(2) :449455.
8Pestalozzi BC, Francis P, Quinaux E, et al. Is risk of centralnervous system ( CNS) relapse related to adjuvant taxanetreatment in node-positive breast cancer. Results of the CNSsubstudy in the intergroup Phase III BIG 02-98 Trial [ J ]. AnnOncol,2008, 19(11) : 1837-1841.
9Gori S, Rimondini S, De Angelis V, et al. Central nervoussystem metastases in HER-2 positive metastatic breast cancerpatients treated with trastuzumab : incidence,survival,and riskfactors[J]. Oncologist, 2007,12(7) :766-773.
10Park YH, Park MJ, Ji SH, et al. Trastuzumab treatmentimproves brain metastasis outcomes through control and durableprolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients[ J]. Br J Cancer,2009,100(6) :894-900.